Viking Therapeutics, Inc.
VKTX Nasdaq
SEC CIK 1607678
Follow Viking Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$183.2M
−101.8% vs same quarter last year
EPS, diluted
−$1.55
−91.4% vs same quarter last year
Operating cash flow
−$138.2M
−47% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$359.6M |
| FY24 | $0 | −$110M |
| FY23 | $0 | −$85.9M |
| FY22 | $0 | −$68.9M |
| FY21 | $0 | −$55M |
| FY20 | $0 | −$39.5M |
| FY19 | $0 | −$25.8M |
| FY18 | $0 | −$22.1M |
| FY17 | $0 | −$20.6M |
| FY16 | $0 | −$14.7M |
| FY15 | $0 | −$23.4M |
| FY14 | $0 | −$21.9M |
| FY13 | - | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | $6.8M |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | $229 |
| FY15 | $38 |
| FY14 | $2 |
| FY13 | - |